share_log

Boston Scientific | 10-Q: Q3 2024 Earnings Report

Boston Scientific | 10-Q: Q3 2024 Earnings Report

波士顿科学 | 10-Q：2024财年三季报
美股SEC公告 ·  2024/11/01 18:38

Moomoo AI 已提取核心信息

Boston Scientific Corporation reported robust Q3 2024 financial results with net sales reaching $4.209 billion, up 19.4% from $3.527 billion in Q3 2023. The growth included 18.2% organic growth and 130 basis points contribution from recent acquisitions. Reported net income was $469 million or $0.32 per share, while adjusted net income reached $937 million or $0.63 per share.The company's performance was primarily driven by strong commercial execution across businesses, particularly the rapid adoption of the Farapulse Pulsed Field Ablation System following its U.S. launch in early 2024. The Cardiology segment led growth with a 29.2% increase to $2.129 billion, while MedSurg segment grew 10.3% to $1.479 billion. Gross profit margin remained stable at 68.8%.Looking ahead, Boston Scientific announced plans to acquire Axonics for $3.67 billion, expected to close in Q4 2024. The company maintains a strong financial position with $2.502 billion in cash and cash equivalents, and $2.750 billion available under its revolving credit facility. Management continues to focus on strategic acquisitions and innovation while maintaining operational efficiency across its global operations.
Boston Scientific Corporation reported robust Q3 2024 financial results with net sales reaching $4.209 billion, up 19.4% from $3.527 billion in Q3 2023. The growth included 18.2% organic growth and 130 basis points contribution from recent acquisitions. Reported net income was $469 million or $0.32 per share, while adjusted net income reached $937 million or $0.63 per share.The company's performance was primarily driven by strong commercial execution across businesses, particularly the rapid adoption of the Farapulse Pulsed Field Ablation System following its U.S. launch in early 2024. The Cardiology segment led growth with a 29.2% increase to $2.129 billion, while MedSurg segment grew 10.3% to $1.479 billion. Gross profit margin remained stable at 68.8%.Looking ahead, Boston Scientific announced plans to acquire Axonics for $3.67 billion, expected to close in Q4 2024. The company maintains a strong financial position with $2.502 billion in cash and cash equivalents, and $2.750 billion available under its revolving credit facility. Management continues to focus on strategic acquisitions and innovation while maintaining operational efficiency across its global operations.
波士顿科学公司报告了2024年第三季度的强劲财务业绩，净销售额达到421.09亿，较2023年第三季度的35.27亿增长了19.4%。增长包括18.2%的有机增长和最近收购贡献的130个基点。报告的净利润为46900万，或者每股0.32美元，而调整后的净利润达到93700万，或者每股0.63美元。公司的业绩主要是通过各业务的强大商业执行来推动的，特别是在2024年初美国发布后，Farapulse脉冲场消融系统的快速采用。心脏病学部门的增长领先，增长29.2%达到21.29亿，而MedSurg部门增长10.3%达到14.79亿。毛利润率保持稳定在68.8%。展望未来，波士顿科学宣布计划以36.7亿收购Axonics，预计在2024年第四季度完成。公司保持强劲的财务实力，拥有25.02亿的现金及现金等价物，以及27.5亿的循环信贷额度可用。管理层继续专注于战略收购和创新，同时在其全球运营中保持运营效率。
波士顿科学公司报告了2024年第三季度的强劲财务业绩，净销售额达到421.09亿，较2023年第三季度的35.27亿增长了19.4%。增长包括18.2%的有机增长和最近收购贡献的130个基点。报告的净利润为46900万，或者每股0.32美元，而调整后的净利润达到93700万，或者每股0.63美元。公司的业绩主要是通过各业务的强大商业执行来推动的，特别是在2024年初美国发布后，Farapulse脉冲场消融系统的快速采用。心脏病学部门的增长领先，增长29.2%达到21.29亿，而MedSurg部门增长10.3%达到14.79亿。毛利润率保持稳定在68.8%。展望未来，波士顿科学宣布计划以36.7亿收购Axonics，预计在2024年第四季度完成。公司保持强劲的财务实力，拥有25.02亿的现金及现金等价物，以及27.5亿的循环信贷额度可用。管理层继续专注于战略收购和创新，同时在其全球运营中保持运营效率。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    艾里德克斯
    IRIX
    -- 0.999
    Helius Medical Technologies
    HSDT
    -- 0.4200
    VolitionRX
    VNRX
    -- 0.550
    HeartSciences
    HSCS
    -- 2.9600
    Outset Medical
    OM
    -- 12.580
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    FOMC维持利率但不确定性高企：美股后市走向如何？
    🎙️讨论 1. 美联储强调政策路径存在“高度不确定性”，你更关注利率预期变化还是经济数据对市场的短期影响？ 2. 若核心通胀维持高位，哪类板块更具交易机会——防御型股票还是科技成长股？ 展开
    联邦公开市场委员会新闻发布会，2025年3月19日